COX-2 Inhibition Antagonizes Intra-Accumbens 2-Arachidonoylglycerol-Mediated Reduction in Ethanol Self-Administration in Rats.


Journal

Alcoholism, clinical and experimental research
ISSN: 1530-0277
Titre abrégé: Alcohol Clin Exp Res
Pays: England
ID NLM: 7707242

Informations de publication

Date de publication:
11 2020
Historique:
received: 19 03 2020
accepted: 01 09 2020
pubmed: 19 9 2020
medline: 9 9 2021
entrez: 18 9 2020
Statut: ppublish

Résumé

Ethanol (EtOH) self-administration is particularly sensitive to the modulation of CB In order to further explore this hypothesis, we analyzed the alterations in operant EtOH self-administration induced by intra-NAc shell infusions of 2-AG itself, the CB Surprisingly, self-administration of 10% EtOH was dose-dependently reduced by either intra-NAc shell SR141716A or 2-AG infusions. Similar effects were found by intra-NAc shell infusions of URB602, suggesting again a role for accumbal 2-AG on the modulation of EtOH intake. Intra-NAc shell anandamide did not alter EtOH self-administration, pointing to a specific role for 2-AG in the modulation of EtOH self-administration. Finally, the inhibitory effect of intra-NAc shell 2-AG on EtOH intake was significantly reversed by pretreatment with nimesulide, suggesting that oxidative metabolites of 2-AG might mediate these inhibitory effects on operant self-administration. We propose that 2-AG signaling in the NAc exerts an inhibitory influence on EtOH consumption through a non-CB1 receptor mechanism involving the COX-2 pathway.

Sections du résumé

BACKGROUND
Ethanol (EtOH) self-administration is particularly sensitive to the modulation of CB
METHODS
In order to further explore this hypothesis, we analyzed the alterations in operant EtOH self-administration induced by intra-NAc shell infusions of 2-AG itself, the CB
RESULTS
Surprisingly, self-administration of 10% EtOH was dose-dependently reduced by either intra-NAc shell SR141716A or 2-AG infusions. Similar effects were found by intra-NAc shell infusions of URB602, suggesting again a role for accumbal 2-AG on the modulation of EtOH intake. Intra-NAc shell anandamide did not alter EtOH self-administration, pointing to a specific role for 2-AG in the modulation of EtOH self-administration. Finally, the inhibitory effect of intra-NAc shell 2-AG on EtOH intake was significantly reversed by pretreatment with nimesulide, suggesting that oxidative metabolites of 2-AG might mediate these inhibitory effects on operant self-administration.
CONCLUSIONS
We propose that 2-AG signaling in the NAc exerts an inhibitory influence on EtOH consumption through a non-CB1 receptor mechanism involving the COX-2 pathway.

Identifiants

pubmed: 32944989
doi: 10.1111/acer.14456
pmc: PMC7680444
mid: NIHMS1643678
doi:

Substances chimiques

Arachidonic Acids 0
Biphenyl Compounds 0
Cyclooxygenase 2 Inhibitors 0
Endocannabinoids 0
Glycerides 0
Polyunsaturated Alkamides 0
Receptor, Cannabinoid, CB1 0
Sulfonamides 0
URB602 0
glyceryl 2-arachidonate 8D239QDW64
Rimonabant RML78EN3XE
anandamide UR5G69TJKH
nimesulide V4TKW1454M

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2158-2165

Subventions

Organisme : NIAAA NIH HHS
ID : R37 AA017447
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA022249
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA017447
Pays : United States
Organisme : NIAAA NIH HHS
ID : P50 AA006420
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA020404
Pays : United States
Organisme : NIAAA NIH HHS
ID : P60 AA006420
Pays : United States
Organisme : NIAAA NIH HHS
ID : R01 AA026999
Pays : United States

Informations de copyright

© 2020 by the Research Society on Alcoholism.

Références

J Biol Chem. 1997 Aug 22;272(34):21181-6
pubmed: 9261124
Nature. 1996 Nov 7;384(6604):83-7
pubmed: 8900284
Pharmacol Ther. 2011 Dec;132(3):215-41
pubmed: 21798285
Eur J Neurosci. 2005 Apr;21(8):2243-51
pubmed: 15869521
J Neurochem. 2003 Feb;84(4):698-704
pubmed: 12562514
Br J Pharmacol. 2015 May;172(10):2427-32
pubmed: 25899710
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10819-24
pubmed: 12136125
Eur J Pharmacol. 1999 Apr 16;370(3):233-40
pubmed: 10334497
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:330-9
pubmed: 26123153
Addict Biol. 2020 May;25(3):e12768
pubmed: 31056846
Neuropsychopharmacology. 2018 Aug;43(9):1840-1850
pubmed: 29748627
Behav Brain Res. 2005 Nov 7;164(2):206-13
pubmed: 16140402
Life Sci. 1998;63(8):PL113-7
pubmed: 9718088
Addict Biol. 2005 Dec;10(4):329-35
pubmed: 16318954
J Biol Chem. 2000 Oct 27;275(43):33744-9
pubmed: 10931854
Psychopharmacology (Berl). 1997 Jul;132(1):104-6
pubmed: 9272766
J Biol Chem. 2014 Sep 5;289(36):24845-62
pubmed: 25037227
Zhongguo Yao Li Xue Bao. 1999 Dec;20(12):1109-14
pubmed: 11189201
ACS Chem Neurosci. 2018 Jul 18;9(7):1552-1559
pubmed: 29722963
Br J Pharmacol. 2018 Apr;175(7):987-993
pubmed: 29520785
Alcohol Clin Exp Res. 2008 Nov;32(11):1976-83
pubmed: 18782338
Open Neuropsychopharmacol J. 2009;2:77-85
pubmed: 27974944
Neuroreport. 2004 Mar 22;15(4):681-5
pubmed: 15094475
J Physiol. 2006 May 1;572(Pt 3):735-45
pubmed: 16484297
Annu Rev Neurosci. 2012;35:529-58
pubmed: 22524785
Elife. 2016 May 10;5:
pubmed: 27162170
Curr Pharm Des. 2004;10(6):659-67
pubmed: 14965328
Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1393-8
pubmed: 12538878
Alcohol Clin Exp Res. 1986 Aug;10(4):436-42
pubmed: 3530023
J Neurosci. 2007 Apr 4;27(14):3695-702
pubmed: 17409233
J Neurochem. 2007 Sep;102(6):1966-1977
pubmed: 17539917
Psychopharmacology (Berl). 2002 Jan;159(2):181-7
pubmed: 11862347
J Neurochem. 2009 Oct;111(1):37-48
pubmed: 19650871
Psychopharmacology (Berl). 2006 Jan;183(4):394-403
pubmed: 16261315

Auteurs

Francisco J Pavon (FJ)

From the, Department of Neuroscience, (FJP, IP, DGS, LHP, AS), The Scripps Research Institute, La Jolla, California, USA.
Instituto de Investigación Biomédica de Málaga, (IBIMA) (FJP, FRF, AS), Hospital Regional Universitario de Málaga, Unidad de Gestión Clínica de Salud Mental, Malaga, Spain.

Ilham Polis (I)

From the, Department of Neuroscience, (FJP, IP, DGS, LHP, AS), The Scripps Research Institute, La Jolla, California, USA.

David G Stouffer (DG)

From the, Department of Neuroscience, (FJP, IP, DGS, LHP, AS), The Scripps Research Institute, La Jolla, California, USA.

Marisa Roberto (M)

Department of Molecular Medicine, (MR, RM-F), The Scripps Research Institute, La Jolla, California, USA.

Rémi Martin-Fardon (R)

Department of Molecular Medicine, (MR, RM-F), The Scripps Research Institute, La Jolla, California, USA.

Fernando Rodriguez de Fonseca (F)

Instituto de Investigación Biomédica de Málaga, (IBIMA) (FJP, FRF, AS), Hospital Regional Universitario de Málaga, Unidad de Gestión Clínica de Salud Mental, Malaga, Spain.

Loren H Parsons (LH)

From the, Department of Neuroscience, (FJP, IP, DGS, LHP, AS), The Scripps Research Institute, La Jolla, California, USA.

Antonia Serrano (A)

From the, Department of Neuroscience, (FJP, IP, DGS, LHP, AS), The Scripps Research Institute, La Jolla, California, USA.
Instituto de Investigación Biomédica de Málaga, (IBIMA) (FJP, FRF, AS), Hospital Regional Universitario de Málaga, Unidad de Gestión Clínica de Salud Mental, Malaga, Spain.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH